BR112023024887A2 - Composto da fórmula i, método para tratar uma doença ou condição dependente de s6k ou mediada por s6k em um sujeito, e, formulação farmaceuticamente aceitável - Google Patents
Composto da fórmula i, método para tratar uma doença ou condição dependente de s6k ou mediada por s6k em um sujeito, e, formulação farmaceuticamente aceitávelInfo
- Publication number
- BR112023024887A2 BR112023024887A2 BR112023024887A BR112023024887A BR112023024887A2 BR 112023024887 A2 BR112023024887 A2 BR 112023024887A2 BR 112023024887 A BR112023024887 A BR 112023024887A BR 112023024887 A BR112023024887 A BR 112023024887A BR 112023024887 A2 BR112023024887 A2 BR 112023024887A2
- Authority
- BR
- Brazil
- Prior art keywords
- dependent
- treating
- subject
- compound
- formula
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 238000009472 formulation Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 230000001419 dependent effect Effects 0.000 abstract 2
- 230000001404 mediated effect Effects 0.000 abstract 2
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 abstract 1
- 108010013238 70-kDa Ribosomal Protein S6 Kinases Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000003176 fibrotic effect Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
composto da fórmula i, método para tratar uma doença ou condição dependente de s6k ou mediada por s6k em um sujeito, e, formulação farmaceuticamente aceitável. são descritos neste documento compostos contendo pirimidina e piridina amina que são inibidores da enzima p70s6k úteis no tratamento de doenças e condições dependentes de s6k ou mediadas por s6k, incluindo, mas não se limitando a câncer, distúrbios metabólicos fibróticos e distúrbios neurológicos específicos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17/334,921 US11866421B2 (en) | 2021-05-31 | 2021-05-31 | Pyrimidine and pyridine amine compounds and usage thereof in disease treatment |
| PCT/US2022/022933 WO2022256075A1 (en) | 2021-05-31 | 2022-03-31 | Pyrimidine and pyridine amine compounds and usage thereof in disease treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023024887A2 true BR112023024887A2 (pt) | 2024-02-15 |
Family
ID=84323512
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023024887A BR112023024887A2 (pt) | 2021-05-31 | 2022-03-31 | Composto da fórmula i, método para tratar uma doença ou condição dependente de s6k ou mediada por s6k em um sujeito, e, formulação farmaceuticamente aceitável |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11866421B2 (pt) |
| EP (1) | EP4346805A1 (pt) |
| JP (1) | JP2024521199A (pt) |
| KR (1) | KR20240016315A (pt) |
| CN (1) | CN117500496A (pt) |
| AU (1) | AU2022284001A1 (pt) |
| BR (1) | BR112023024887A2 (pt) |
| CA (1) | CA3220090A1 (pt) |
| IL (1) | IL308924A (pt) |
| WO (1) | WO2022256075A1 (pt) |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2643313T (pt) * | 2010-11-24 | 2016-10-11 | Merck Patent Gmbh | Quinazolina carboxamida azetidinas |
| EP2755958B9 (en) | 2011-09-12 | 2018-02-28 | Merck Patent GmbH | Aminopyrimidine derivatives for use as modulators of kinase activity |
| RS56534B1 (sr) | 2011-09-12 | 2018-02-28 | Merck Patent Gmbh | Novi imidazol akmini kao modulatori aktivnosti kinaza |
| MX2014013407A (es) | 2012-05-22 | 2014-11-26 | Hoffmann La Roche | Dipiridilaminas sustituidas y uso de las mismas. |
| WO2014093230A2 (en) | 2012-12-10 | 2014-06-19 | Merck Patent Gmbh | Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity |
| ES2746756T3 (es) | 2013-03-11 | 2020-03-06 | Merck Patent Gmbh | Derivados de 6-[4-(1H-imidazol-2-il)piperidin-1-il]pirimidin-4-amina como moduladores de la actividad cinasa |
| JP6560243B2 (ja) | 2014-02-11 | 2019-08-14 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | キナーゼ活性のモジュレーターとしてのピリミジンイミダゾールアミン |
| US10851082B2 (en) | 2015-10-28 | 2020-12-01 | Northwestern University | Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (MNK1) and 2 (MNK2) |
| LT3371165T (lt) | 2015-11-04 | 2022-05-10 | Merck Patent Gmbh | Btk inhibitorius, naudojamas vėžiui gydyti |
| EP4295910A3 (en) | 2015-11-17 | 2024-03-20 | Merck Patent GmbH | Methods for treating multiple sclerosis using pyrimidine and pyridine compounds with btk inhibitory activity |
| CN106045918B (zh) | 2016-06-28 | 2019-02-01 | 山东大学 | 具有Akt抑制活性的取代嘧啶类衍生物及其制备方法与应用 |
| KR102195348B1 (ko) | 2018-11-15 | 2020-12-24 | 에이치케이이노엔 주식회사 | 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물 |
| US20220289686A1 (en) | 2021-03-09 | 2022-09-15 | Washington University | Compositions of nrf2 inhibiting agents and methods of use thereof |
-
2021
- 2021-05-31 US US17/334,921 patent/US11866421B2/en active Active
-
2022
- 2022-03-31 WO PCT/US2022/022933 patent/WO2022256075A1/en active Application Filing
- 2022-03-31 CN CN202280039471.6A patent/CN117500496A/zh active Pending
- 2022-03-31 KR KR1020237044453A patent/KR20240016315A/ko unknown
- 2022-03-31 EP EP22816603.9A patent/EP4346805A1/en active Pending
- 2022-03-31 IL IL308924A patent/IL308924A/en unknown
- 2022-03-31 JP JP2023573487A patent/JP2024521199A/ja active Pending
- 2022-03-31 AU AU2022284001A patent/AU2022284001A1/en active Pending
- 2022-03-31 BR BR112023024887A patent/BR112023024887A2/pt unknown
- 2022-03-31 CA CA3220090A patent/CA3220090A1/en active Pending
-
2023
- 2023-12-06 US US18/531,575 patent/US20240124423A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20240124423A1 (en) | 2024-04-18 |
| JP2024521199A (ja) | 2024-05-28 |
| CA3220090A1 (en) | 2022-12-08 |
| IL308924A (en) | 2024-01-01 |
| US20220396564A1 (en) | 2022-12-15 |
| WO2022256075A1 (en) | 2022-12-08 |
| US11866421B2 (en) | 2024-01-09 |
| CN117500496A (zh) | 2024-02-02 |
| KR20240016315A (ko) | 2024-02-06 |
| EP4346805A1 (en) | 2024-04-10 |
| AU2022284001A1 (en) | 2023-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020002146A1 (es) | Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer. | |
| PH12020552148A1 (en) | Purinone compounds and their use in treating cancer | |
| EA202090955A1 (ru) | Способы применения ингибиторов ehmt2 в лечении или предупреждении нарушений со стороны крови | |
| PH12019501350A1 (en) | Amino-triazolopyridine compounds and their use in treating cancer | |
| MX2020007092A (es) | Metodos de uso de inhibidores ehmt2 para tratar o prevenir transtornos sanguineos. | |
| MX2023007192A (es) | Inhibidores de prmt5. | |
| BR112015011497A2 (pt) | composto, formulação farmacêutica, produto de combinação, e, método de tratamento de uma doença | |
| WO2016118951A3 (en) | Heterocyclic itk inhibitors for treating inflammation and cancer | |
| BR112022016382A2 (pt) | Triptaminas específicas para o uso no tratamento de doenças do humor | |
| BR112022000019A2 (pt) | Composto da fórmula, composição farmacêutica e método de tratamento de câncer | |
| BR112017007662A2 (pt) | composto, composição farmacêutica, processo de elaboração de uma composição farmacêutica, método de tratamento de distúrbio ou doença relativa a er, kit de tratamento e uso de composto | |
| MX2021010888A (es) | Derivados heteroaromaticos y aromaticos heterobiciclicos para el tratamiento de trastornos relacionados con ferroptosis. | |
| BRPI0622054B8 (pt) | composto e composição farmacêutica | |
| ECSP099821A (es) | METABOLITOS DEL INHIBIDOR DE JANUS QUINASA (R)-3-(4-(7H-PIRROLO[2,3-d]PIRIMIDIN-4-IL)-1H-PIRAZOL-1-IL)-3-CICLOPENTILPROPANONITRILO | |
| CL2022000998A1 (es) | Inhibidores de las cinasas raf | |
| CL2021002681A1 (es) | Inhibidores de la dihidroorotato deshidrogenasa. | |
| BR112015026297A2 (pt) | terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer | |
| PL410665A1 (pl) | Inhibitory arginazy oraz ich zastosowania terapeutyczne | |
| MX2021011928A (es) | Composiciones y metodos para el tratamiento de enfermedades o trastornos asociados con kras. | |
| MX2023009222A (es) | Inhibidores tricíclicos-amido-bicíclicos de prmt5. | |
| WO2018183370A3 (en) | Kdm4 inhibitors | |
| MX2022005749A (es) | Inhibidores de egfr alostericos y metodos de uso de los mismos. | |
| PH12019502086A1 (en) | Deuterated imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | |
| CR20230362A (es) | Inhibidores de cdk2 y métodos de uso de los mismos | |
| BR112019006880A2 (pt) | compostos e composições para tratamento de leishmaniose e métodos de diagnóstico e tratamen-to usando os mesmos |